Vitae Pharmaceuticals to Present at JMP Securities Life Sciences Conference

FORT WASHINGTON, Pa., June 14, 2016 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ: VTAE), a clinical-stage biotechnology company, today announced that Richard Gregg, M.D., Chief Scientific Officer, will present a company overview at the JMP Securities Life Sciences Conference on Tuesday, June 21, 2016 at 1:00 p.m. EDT at the St. Regis New York.

A live audio webcast of the presentation will be available via the "Investor Relations" page of the Vitae website, www.vitaepharma.com. A replay of the webcast will be archived on Vitae's website for 90 days following the presentation.

About Vitae Pharmaceuticals

Vitae Pharmaceuticals is a clinical-stage biotechnology company developing first-in-class product candidates with potential to transform the treatment paradigm for patients with significant unmet medical needs. Initial indications being pursued include psoriasis, other autoimmune disorders, and atopic dermatitis. Vitae’s lead clinical assets include VTP-43742, an oral RORyt inhibitor currently being studied in patients with moderate to severe psoriasis, and VTP-38543, an LXRβ selective agonist being studied in patients with mild to moderate atopic dermatitis.

For additional information, please visit the company's website at www.vitaepharma.com.

 

INVESTORS:
Vitae Pharmaceuticals, Inc.
Richard S. Morris, CPA
Chief Financial Officer
(215) 461-2000
[email protected]

Westwicke Partners
John Woolford
(443) 213-0506
[email protected]

MEDIA:
6 Degrees PR
Tony Plohoros
(908) 591-2839
[email protected]

Source: Vitae Pharmaceuticals, Inc.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Exostar Technology Enables Fujitsu's Trusted Supply Chainservice for Japan's Defense and Critical Infrastructure Sectors
• Hundreds of Young People Join UN Talks on the Future of AI
• Nickel & Nickel Offers a Vineyard-by-Vineyard Exploration of Napa Valley Cabernet